Updated:
Shuttle Pharmaceuticals Holdings, Inc.
Shuttle Pharmaceuticals Holdings, Inc. is a publicly traded biopharmaceutical firm (NASDAQ: SHPH) that develops therapies to enhance the efficacy of...
Shuttle Pharmaceuticals Holdings, Inc.
Shuttle Pharmaceuticals Holdings, Inc. is a publicly traded biopharmaceutical firm (NASDAQ: SHPH) that develops therapies to enhance the efficacy of radiation and immunotherapy for cancer treatment. Its lead pipeline candidate targets hypoxia in solid tumors. The company has reported no founding year or named principals in public filings. The firm focuses on therapeutic development rather than managing external capital. It has not disclosed a team size, deployment figures, or additional offices. Shuttle Pharmaceuticals operates primarily in North America, with no confirmed international footprint. As a publicly held entity, Shuttle Pharmaceuticals differs from a family office or asset manager. Its structure aligns with a research-stage biotechnology company. No philanthropic or related investment vehicles have been identified. The firm's last significant public event was a July 2023 licensing agreement to develop its lead compound (per SEC filings, July 2023). Shuttle Pharmaceuticals' key structural differentiator is its public listing, which provides capital access distinct from private family offices. Its mandate is purely therapeutic discovery, not capital management for outside allocators.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
—
City
—
Corporate office
—
Sector focus
Frequently asked questions
What type of entity is Shuttle Pharmaceuticals Holdings, Inc.?
Shuttle Pharmaceuticals Holdings, Inc. is a publicly traded biopharmaceutical company listed on NASDAQ under the ticker SHPH. It is not a family office, asset manager, or investment firm; it focuses on developing novel therapeutics for cancer treatment (per SEC filings).
Does Shuttle Pharmaceuticals manage capital for outside investors?
No. Shuttle Pharmaceuticals Holdings, Inc. operates as a development-stage drug discovery and development company. It does not manage third-party capital, nor does it have a disclosed AUM or investment team.
What is the primary focus of Shuttle Pharmaceuticals' pipeline?
The company's pipeline centers on small-molecule therapeutics designed to sensitize cancer cells to radiation and enhance immune response against tumors (per the firm's official communications). Its lead candidate targets HIF-1α in hypoxic tumors.
Who are the principals or founders of Shuttle Pharmaceuticals?
Public filings identify key executives including Chairman and CEO Anatoly Dritschilo, M.D., who founded the company (per SEC filings, 2023). However, no complete list of investment principals is disclosed.
Is Shuttle Pharmaceuticals related to any family office or family wealth?
No verified family office connection has been publicly identified. The firm's ownership includes public shareholders, with the founding executive holding a significant stake (per SEC filings, 2023).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: